Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methadone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Methadone | ACTIVE_COMPARATOR | Dose of methadone must not change from 1 week prior to study start and through the duration of the study. |
| Lersivirine + Methadone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Methadone | DRUG | Methadone 50 - 150 mg QD (Day 1) |
| Lersivirine + Methadone | DRUG | Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11) |
Inclusion Criteria: * Healthy male and/or female subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history except drug abuse), full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory test...
Methadone is a small molecule being studied in healthy volunteers to assess its pharmacokinetics. In the completed Phase 1 trial, researchers estimated the effect of lersivirine on the pharmacokinetics of S- and R-methadone. The study enrolled 13 participants in the United States and was active-controlled, though it was not randomized or double-blinded.
Methadone is being developed by Pfizer, Inc., which trades under the ticker PFE. The company is conducting clinical research on this small molecule in the therapeutic area of Other, with a focus on healthy volunteers. Pfizer's development program includes a completed Phase 1 trial involving 13 participants.
Methadone is in Phase 1 clinical development. The investigational drug is being studied in healthy volunteers, and the single trial in its development program has been completed. This Phase 1 study was active-controlled and enrolled 13 participants in the United States. Methadone remains in early-stage clinical research.
Methadone has one completed clinical trial, NCT01099748, titled "Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone." This Phase 1 study enrolled 13 healthy volunteers in the United States, with participants aged 18 years and older. The trial was active-controlled, not randomized or double-blinded, and included both sexes.
Methadone is an investigational drug in clinical development and has not been approved by the FDA. It is currently in Phase 1 trials, with one completed study in healthy volunteers. The development program is being conducted by Pfizer, Inc. Approval status is not indicated beyond its investigational stage.